Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human IL-1β Monoclonal Antibody

Catalog No.: YR0006

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Canakinumab is a recombinant human monoclonal antibody which binds to IL-1β (interleukin-1 beta). It’s mode of action is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009, the FDA approved canakinumab for the treatment of cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory syndromes. In September 2016, the FDA approved it’s use for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS),hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). In June 2020, canakinumab was FDA-approved for the indication to treat active Still's disease, including adult-onset Still's disease (AOSD).

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Canakinumab Biosimilar

Isotype
Human IgG1 kappa

Immunogen

RecommendedIsotype Control(s)

Recommended Dilution Buffer
1×PBS pH 7.3

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn


Product Information

Production
Purified from cell culture supernatant in an animal-free facility


Purification
Protein A or G purification

Storage
Store at -20℃

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human IL-1β (Research Grade Canakinumab Biosimilar) Monoclonal Antibody to IL-1β. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human IL-1β SPR assay. Determined through SPR assay, the Human Anti-Human IL-1β (Research Grade Canakinumab Biosimilar) Monoclonal Antibody is capable of binding to Human IL-1β with an affinity constant of 0.1067 nM.